As an adaptive mechanism to evade the host immune surveillance, cancer cells have evolved to hijack the PD-1/PD-L1 signaling by constitutively expressing PD-L1 or PD-L2 to activate the inhibitory receptor PD-1 found on the tumor-infiltrating lymphocytes (TILs). Here, CD274 is linked to neoplasm.